Positive allosteric modulator of mGlu group I receptors (pEC50 value is 7.16 for the rat mGlu1a receptor). Exhibits activity at all group I receptors, including human and rat mGlu1 and rat mGlu5. Enhances the effects of (S)-DHPG in CA3 neurons (EC50 = 95 nM).
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 325.36. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.07 mL||15.37 mL||30.74 mL|
|5 mM||0.61 mL||3.07 mL||6.15 mL|
|10 mM||0.31 mL||1.54 mL||3.07 mL|
|50 mM||0.06 mL||0.31 mL||0.61 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Knoflach et al (2001) Positive allosteric modulators of metabotropic glutamate receptor: Characterizationn, mechanism of action, and binding site. Proc.Natl.Acad.Sci. 98 13402 PMID: 11606768
Hempstapat et al (2006) A novel class of positive allosteric modulators of metabotropic glutamate receptor subtype 1 interact with a site distinct from that of negative allosteric modulators. Mol.Pharmacol. 70 616 PMID: 16645124
If you know of a relevant reference for Ro 67-4853, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Ro67-4853 PAM positive allosteric modulator modulators metabotropic glutamate receptor 1 enhancer mGlu1 receptors Glutamate (Metabotropic) Group I Receptors
Citations for Ro 67-4853
Citations are publications that use Tocris products.
Currently there are no citations for Ro 67-4853. Do you know of a great paper that uses Ro 67-4853 from Tocris? If so please let us know.
Literature in this Area
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Huntington's Disease Poster
Huntington's disease (HD) is a monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the MSN intracellular signaling pathways implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.